Newly Identified TLR9 Stimulant, M6-395 Is a Potent Polyclonal Activator for Murine B Cells

Mi-Hee Park¹, Yu-Jin Jung² and Pyeung-Hyeun Kim¹*

¹Department of Molecular Bioscience, College of Biomedical Science, ²Department of Biological Science, College of Natural Science, Kangwon National University, Chuncheon 200-701, Korea

Background: Toll-like receptors (TLRs) have been extensively studied in recent years. However, functions of these molecules in murine B cell biology are largely unknown. A TLR4 stimulant, LPS is well known as a powerful polyclonal activator for murine B cells. Methods: In this study, we explored the effect of a murine TLR9 stimulant, M6-395 (a synthetic CpG ODNs) on B cell proliferation and Ig production. Results: First, M6-395 was much more potent than LPS in augmenting B cell proliferation. As for Ig expression, M6-395 facilitated the expression of both TGF-β1-induced germ line transcript α (GLTα) and IL-4-induced GLTγ1 as levels as those by LPS and Pam3CSK4 (TLR1/2 agonist) : a certain Ig GLT expression is regarded as an indicative of the corresponding isotype switching recombination. However, IgA and IgG1 secretion patterns were quite different--these Ig isotype secretions by M6-395 were much less than those by LPS and Pam3CSK4. Moreover, the increase of IgA and IgG1 production by LPS and Pam3CSK4 was virtually abrogated by M6-395. The same was true for the secretion of IgG3. We found that this unexpected phenomena provoked by M6-395 is attributed, at least in part, to its excessive mitogenic nature. Conclusion: Taken together, these results suggest that M6-395 can act as a murine polyclonal activator but its strong mitogenic activity is unfavorable to Ig isotype switching.

INTRODUCTION

All living organisms are exposed constantly to microorganisms that are present in the environment and need to cope with invasion of these organisms into the body. Toll-like receptors (TLRs) are of interest to immunologists because of their front-line role in the initiation of innate immunity against invading pathogens (1). Engagement of TLRs by the cognate antigen triggers clonal expansion of the lymphocyte and further production of antigen-specific antibodies, TLR1 and TLR2 sense bacterial triacylated lipopeptides, while TLR4 and TLR9 recognizes LPS and CpG-containing DNA motifs, respectively (1). Among these, TLR9 is expressed in the endoplasmic reticulum and recruited to endosomal/lysosomal compartments once stimulated (2).

Recent studies reveal that TLR stimulation on B cells can control isotype switching. TLR and MyD88 are required for class switching to the pathogenic IgG2a and IgG2b isotypes but not for development of IgM autoantibodies (3). TLR9 can regulate isotype switching to IgG2a directly by interacting with B cells rather than indirectly by inducing Th1 responses (4). Furthermore, CpG, but not LPS, upregulates T-bet expression in B cells and induces IgG2a whereas it decreases IgG1 and IgE production (5). Other than these studies, the exact role of TLR-9 in Ig synthesis has not been thoroughly investigated yet. Nevertheless, TLR9 ligands would be regarded as the vaccine adjuvant since it enables B cells to stimulate Ig syntheses.

Recently, it has been demonstrated that a synthetic CpG oligodeoxynucleotide (ODN) M6-395 function as TLR9-specific ligands, making them useful in the study of TLR9 functionality and signaling in mice (6). In the present study, we inves-
tigated the functions of M6-395 in the context of Ig synthesis paralleling with LPS and Pam3CSK4 (TLR1/2 ligand). In essence, we found that M6-395 can act as a B cell polyclonal activator and that it is much more mitogenic than LPS and Pam3CSK4.

MATERIALS AND METHODS

Animals
BALB/C mice were purchased from Daehan Biolink Co. (Seoul, Korea) and maintained on an 8:16 h light:dark cycle in an animal environmental control chamber (Myung Jin Inst. Co., Seoul, Korea). Animal care was in accordance with the institutional guidelines of Kangwon National University. Eight- to twelve-week-old female mice were used in this study.

Reagents
TGF-β1 and IL-4 were purchased from R&D Systems (Minneapolis, MN, USA). 2,2′-Azinobis-(3-ethylbenzthiazoline sulphonic acid) (ABTS) and LPS (Escherichia coli 0111:B4) was from Sigma Chemical Co. (St. Louis, MO, USA). Pam3CSK4 was from Invivogen (San Diego, CA, USA). TRIZOL reagent and CFSE kit were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). The antibodies used in ELISA were purchased from Southern Biotechnology (Birmingham, AL).

B cell preparations and cell culture
Mouse spleen B cell population was prepared as described before (7).

A total of 2 × 10^6 cells/well were cultured in flat-bottomed, 24-well tissue culture plates (SPL, Korea) in a volume of 2 ml complete medium or a total of 2×10^5 cells/well were cultured in flat-bottomed, 96-well tissue culture plates in a volume of 200 μl complete medium with added stimulants.

Isotype-specific ELISA
Produced antibodies were detected by using a modified ELISA (8). Isotype specificity was confirmed by assaying isotype-specific antibodies against a panel of myeloma proteins of the IgG isotypes, IgA and IgM. The assay was sensitive to antibody concentrations of 1 to 10 ng/ml.

RNA preparation and RT-PCR
RNA preparation, reverse transcription, and PCR were performed as described previously (7). PCR primers were synthesized by Bioneer Corp. (Seoul, Korea). First, we found that TLR1, TLR2, TLR4, and TLR9 were expressed in mouse B cells at the transcriptional level (Fig. 1A). LPS, a TLR4 stimulant, is a powerful mitogen for murine B cells. Therein, we examined the mitogenic effect of M6-395 on the viability of mouse B cells paralleling with LPS, LPS, at the concentration of 12.5 μg/ml, markedly increased B cell viability up to day 4 (Fig. 1B). Herein, 100 nM of M6-395 was comparable to 12.5 μg/ml of LPS in the increment of cell viability. In fact, the former appears to be more mitogenic against mouse B cells than the latter since it took 3 days for M6-395 and 4 days for LPS to reach the maximal viability. We further characterized the mitogenic
Figure 1. Effect of M6-395 on the viability and proliferation of mouse spleen B cells. (A) TLR expression was detected by RT-PCR in BALB/C mouse spleen B cells. (B) Mouse spleen B cells were cultured with LPS (12.5 μg/ml) and M6-395 (20 nM, 100 nM). Cell viability was assessed using trypan blue staining. (C) Mouse spleen B cells were cultured with LPS (12.5 μg/ml), Pam3CSK4 (0.5 μg/ml) and M6-395 (100 nM). B cell proliferation was assessed after 2 and 3 days analyzing the dilution of CFSE.

Figure 2. Effect of M6-395 on IgG production and AID expression. Mouse spleen B cells were cultured with LPS (12.5 μg/ml), Pam3CSK4 (0.5 μg/ml) and M6-395 (100 nM) for 7 days or 48 h. (A) Supernatants were collected, and IgG productions were determined by isotype-specific ELISA. Data are means of triplicate samples±SEM. (B) Levels of AID and β-actin were measured by RT-PCR after 48 h.
property of M6-395 by CFSE assay. In this, Pam3CSK4 (a TLR1/2 stimulant) was also included since it was expressed in B cells (Fig. 1) and thus expected to be stimulatory for B cells. As shown in Fig. 1C, M6-395 stimulated B cell proliferation much better than LPS or Pam3CSK4. This finding was consistent with the earlier report that CpG promotes cell cycle entry and cell survival (10).

Effect of M6-395 on the expression of Ig isotypes and AID in mouse B cells
Since M6-395 strongly increased B cell proliferation, it was important to explore whether it affects Ig production by B cells. As shown in Fig. 2A, we found that M6-395 facilitated secretion of IgM, IgG subclasses, and IgA. However, the amounts of each Ig in the presence of M6-395 were less than those in the presence of LPS or Pam3CSK4. Subsequently, we examined if M6-395 can regulate expression of activation-induced cytidine deaminase (AID), which is a critical enzyme for general class switching recombination (CSR) from IgM to other Ig isotypes (11,12). As shown in Fig. 2B, M6-395, like LPS and Pam3CSK4, clearly induced AID expression at the transcriptional level. These results indicate that
M6-395 enhances IgG and IgA secretion, at least in part, through AID-mediated Ig CSR.

**Effect of M6-395 on TGF-β1-inducible IgA and IL-4-inducible IgG1 CSR**

Since M6-395 can enhance Ig CSR as shown in Fig. 2A, it was necessary to determine whether M6-395 supports a certain cytokine-specific Ig CSR, TGF-β1 and IL-4 are potent IgA and IgG1 switching factors, respectively (13,14). Given that the expression of a particular Ig germline transcript (GLT) is considered to be an indicative of such Ig CSR (15), we examined the effects of M6-395 on TGF-β1-inducible GLTα and IL-4-inducible GLTγ1 expression. M6-395, like LPS and Pam3CSK4, well supported both cytokine-induced GLT expression, indicating that M6-395 has an activity to induce Ig CSR (Fig. 3A). Interestingly, the increasing GLTα and GLTγ1 expression by M6-395 was not further augmented in the presence of additional LPS or Pam3CSK4, suggesting that the three reagents may share common pathway toward general Ig CSR event.

On the other hand, both TGF-β1-induced IgA secretion and IL-4-induced IgG1 secretion were apparently increased by M6-395 but the amounts of each isotype were much less than those by LPS and Pam3CSK4 (Fig. 3B). Moreover, the striking increase of IgA and IgG1 by either LPS or Pam3CSK4 were virtually abolished in the presence of additional M6-395. These are totally unexpected results, which are also sharply contrasted to those seen in expression patterns of GLTα and GLTγ1. This inhibitory effect of M6-395 was more dramatic in IgG3 secretion by LPS and Pam3CSK4 (Fig. 3B).

We speculated that the inhibitory function of M6-395 in LPS- and Pam3CSK4-stimulated Ig production is at least in part owing to an inherent anti-proliferative activity of M6-395. Therein, the present study tested the combined effect of LPS and M6-395 on the proliferation of splenic B cells. As shown in Fig. 4, proliferation of B cells treated with LPS plus M6-395 was greater than that of LPS and M6-395 each alone, Taken together, an excess cell proliferation-promoting nature of M6-395 is certainly unfavorable toward B cell differentiation into Ig synthesis.

**Concluding remarks**

In the present study, we found that M6-395, a newly identified TLR9 stimulant, is a powerful polyclonal activator for mouse B cells. Surprisingly, this property of M6-395 is even greater than that of LPS, a well-known B cell polyclonal activator. Nevertheless, we also realized that this strong proliferation enhancing activity of M6-395 is detrimental for the ultimate Ig synthesis though Ig CSR event is little affected. Taken together, the results from the present study indicate that M6-395 could be utilized for a direct B cell adjuvant for vaccination. To optimize this adjuvant activity of M6-395, one should consider the dynamics between proliferation and differentiation of B cells initiated by this chemical.

**ACKNOWLEDGEMENTS**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2010-0017247 and The Regional Core Research Program/Medical & Bio-Material Research Center) and by the 2nd stage of the Brain Korea 21 program.
CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. O’Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364, 2007.
2. Latz E, Schoenemeyer A, Visentin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espévak T, Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome, Nat Rev Immunol 5:190-198, 2004.
3. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV: TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SJL, J Exp Med 203:553-561, 2006.
4. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF: TLR9 signaling in B cells determines class switch recombination to IgG2a, J Immunol 178:2415-2420, 2007.
5. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB: CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells, Nat Immunol 4:697-693, 2003.
6. Choi SS, Chung E, Jung YJ: Newly identified CpG ODNs, M5-30 and M6-395, stimulate mouse immune cells to secrete TNF-alpha and enhance Th1-mediated immunity, J Microbiol 48:512-517, 2010.
7. Park SR, Lee JH, Kim PH: Smad3 and Smad4 mediate transforming growth factor-beta1-induced IgA expression in murine B lymphocytes, Eur J Immunol 31:1706-1715, 2001.
8. Murray PD, McKenzie DT, Swain SL, Kagnoff MF: Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression, J Immunol 139:2669-2674, 1987.
9. Hayashi EA, Akira S, Nobrega A: Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2, J Immunol 174:2699-2697, 2005.
10. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF: CpG oligodeoxynucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry, J Immunol 160:5898-5906, 1998.
11. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinakai Y, Honjo T: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme, Cell 102:553-563, 2000.
12. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Essey F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A: Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2), Cell 102:565-575, 2000.
13. Kim PH, Kagnoff MF: Transforming growth factor beta 1 increases IgA isotype switching at the clonal level, J Immunol 145:3773-3778, 1990.
14. Berton MT, Uhr JW, Vitetta ES: Synthesis of germ-line gamma 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon gamma, Proc Natl Acad Sci U S A 86:2829-2833, 1989.
15. Stavnezer J: Molecular processes that regulate class switching, Curr Top Microbiol Immunol 245:127-168, 2000.